Send to

Choose Destination
Thorac Cancer. 2016 Jul;7(4):428-36. doi: 10.1111/1759-7714.12350. Epub 2016 May 13.

Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.

Author information

Lung Cancer Center, West China Hospital Sichuan University Chengdu China.
School of Dentistry, Department of Pathology University of California Los Angeles California USA.
Department of Biostatistics, MD Anderson Cancer Center University of Texas Houston Texas USA.
Department of Thoracic Surgery, Henan Cancer Hospital University of Zhengzhou Zhengzhou China.
Department of Thoracic Surgery, Jiangsu Cancer Hospital Nanjing Medical University Nanjing China.
Laboratory of Lung Development and Disease West China Second University Hospital, Sichuan University Chengdu China.
Department of Cancer Epidemiology Cancer Hospital/Institute, Chinese Academy of Medical Sciences Beijing China.



This article describes a pilot study evaluating a novel liquid biopsy system for non-small cell lung cancer (NSCLC) patients. The electric field-induced release and measurement (EFIRM) method utilizes an electrochemical biosensor for detecting oncogenic mutations in biofluids.


Saliva and plasma of 17 patients were collected from three cancer centers prior to and after surgical resection. The EFIRM method was then applied to the collected samples to assay for exon 19 deletion and p.L858 mutations. EFIRM results were compared with cobas results of exon 19 deletion and p.L858 mutation detection in cancer tissues.


The EFIRM method was found to detect exon 19 deletion with an area under the curve (AUC) of 1.0 in both saliva and plasma samples in lung cancer patients. For L858R mutation detection, the AUC of saliva was 1.0, while the AUC of plasma was 0.98. Strong correlations were also found between presurgery and post-surgery samples for both saliva (0.86 for exon 19 and 0.98 for L858R) and plasma (0.73 for exon 19 and 0.94 for L858R).


Our study demonstrates the feasibility of utilizing EFIRM to rapidly, non-invasively, and conveniently detect epidermal growth factor receptor mutations in the saliva of patients with NSCLC, with results corresponding perfectly with the results of cobas tissue genotyping.


EGFR mutation; liquid biopsy; lung cancer; saliva diagnostics

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center